Market Place
Sourcing Support
Kadimastem Calls Special Meeting To Approve Merger With NLS
16 Jan 2025 //
PR NEWSWIRE
NLS Pharmaceutics Secures $500K in Fundraising, Share Price +48%
08 Jan 2025 //
PR NEWSWIRE
NLS Pharmaceutics and Kadimastem File F-4 for Proposed Merger
30 Dec 2024 //
PR NEWSWIRE
NLS and Kadimastem Submit Request for FDA Pre-IND Meeting for T1D
19 Dec 2024 //
ACCESSWIRE
Pluri To Manufacture Kadimastem`s Cell Therapy Product Candidates
18 Jul 2024 //
GLOBENEWSWIRE
Kadimastem Receives Approval of Patent Registration for Its Cell Selection
28 Sep 2022 //
PRNEWSWIRE
Kadimastem Granted a Patent in Israel for the Directed Differentiation
09 Mar 2021 //
PRNEWSWIRE
Kadimastem Granted a Patent in Israel for the Directed of Astrocytes
09 Mar 2021 //
PRNEWSWIRE
Kadimastem Announces Encouraging Results of Cohort B of its Phase 1/2a AstroRx®
15 Dec 2020 //
PRNEWSWIRE
Kadimastem Reports +ve Interim Results of Cohort B AstroRx® Ph 1/2a in ALS
03 Aug 2020 //
PRNEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.